EcoDrugPlus

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSMAMG00000005662
Gene Symbol: PTGS1
2 Cross references
212 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2b

Ensembl ID : ENSMAMG00000008217
Gene Symbol: PTGS2B
3 Cross references
214 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSMAMG00000027938
Gene Symbol: LOC113145857
2 Cross references
191 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSMAMG00000022977
Gene Symbol: PSMA1
2 Cross references
270 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSMAMG00000000647
Gene Symbol: PSMA2
2 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSMAMG00000025722
Gene Symbol: PSMA3
3 Cross references
238 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSMAMG00000023077
Gene Symbol: PSMA4
2 Cross references
186 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSMAMG00000008466
Gene Symbol: PSMA5
2 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6b

Ensembl ID : ENSMAMG00000007936
Gene Symbol: PSMA6B
3 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSMAMG00000013734
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSMAMG00000020299
Gene Symbol: PSMB1
2 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSMAMG00000019127
Gene Symbol: PSMB10
2 Cross references
171 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).